Your session is about to expire
← Back to Search
Acapatamab for Prostate Cancer
Study Summary
This trial will test new treatments for men with mCRPC. The goal is to find out if they are safe and effective.
- Metastatic Castration Resistant Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must participate in all aspects of the study.
- Group 1: Acapatamab and Abiraterone: Dose Expansion Asia Cohort
- Group 2: Acapatamab and Abiraterone: Dose Expansion
- Group 3: Acapatamab and Enzalutamide: Dose Expansion
- Group 4: Acapatamab and AMG 404: Dose Exploration
- Group 5: AMG 404 Monotherapy
- Group 6: Acapatamab and AMG 404: Dose Expansion Asia Cohort
- Group 7: Acapatamab and AMG 404: Dose Expansion
- Group 8: Acapatamab and Enzalutamide: Dose Exploration
- Group 9: Acapatamab and Abiraterone: Dose Exploration
- Group 10: Acapatamab and Enzalutamide: Dose Expansion Asia Cohort
- Group 11: Acapatamab Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the eligibility criteria of this experiment limited to individuals under 35 years old?
"This medical trial is enrolling patients who are of legal age and below 99 years old."
What is the intended outcome of this research endeavor?
"The core focus of this study, estimated to take Up to 3 years, is the count of participants who endure dose limiting toxicities (DLTs). Additionally, researchers will analyze Neutrophil-to-lymphocyte ratio over Parts 1, 2 and 3; likewise they shall measure Concentration of hemoglobin and Time to progression during those same periods."
Are there multiple locations in the United States facilitating this clinical trial?
"This clinical trial is being carried out at Norton Cancer Institute in Louisville, Kentucky, University of Chicago in Chicago, Illinois, and University of California at Irvine Medical Center in Orange, California as well as an additional 7 medical centres."
To whom is this research opportunity available?
"This trial is currently seeking 136 individuals aged 18 to 99 with existing castration. Other eligibility requirements include being of legal age within the participant's country."
How many participants are presently enrolled in this research endeavor?
"Unfortunately, for this particular trial, recruitment is currently suspended. The study was first posted on the 15th of January 2021 and last updated in June 2022. On the other hand, if you are seeking alternatives there are 1258 studies recruiting patients with castration and 171 trials looking for individuals to participate in Acapatamab research."
Are there any past investigations involving Acapatamab?
"Currently, 171 Acapatamab medical trials are in progress with 45 of them being conducted at the Phase 3 level. The majority of these studies can be found in Leicester, Pennsylvania and beyond this there are another 10,082 locations running clinical research for this particular treatment."
Is the current research study seeking additional participants?
"This clinical trial, which was posted on January 15th 2021 and last updated June 20th 2022 is no longer welcoming new participants. Nonetheless, 1429 other experimental studies are currently recruiting patients."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger